Anti-VLA-4 antibodies with reduced effector function

CN112867394B9Active Publication Date: 2024-12-06BIOGEN MA INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980051574.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-12
Filing Date
2019-05-31
Publication Date
2024-12-06
Estimated Expiration
2039-05-31

Smart Images

  • Figure CN112867394B9_ABST
    Figure CN112867394B9_ABST
Patent Text Reader

Abstract

The present invention relates to anti-VLA-4 antibodies and binding fragments thereof. The present invention also includes polynucleotides encoding the antibodies and binding fragments thereof and methods of making the antibodies and binding fragments thereof. The present invention also includes methods of treating patients suffering from multiple sclerosis and / or epilepsy by administering the antibodies and binding fragments thereof. The present invention also includes methods of reducing the susceptibility of recombinant anti-α4 antibodies or binding fragments thereof to perturbations.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to α4 binding antibodies and fragments thereof.

[0002] Sequence Listing

[0003] This application contains information that has been submitted by EFS-Web and is incorporated herein by reference in its entirety. Background of the Invention

[0005] Integrins are cell surface receptors that mediate cell-cell and cell-matrix interactions.

[0006] VLA-4 (also known as α4β1) and α4β7 play a significant role in the pathophysiology of inflammatory diseases.

[0007] α4β1 binds to two protein ligands, VCAM-1 or fibronectin (e.g.

[0008] Humanized antibodies can be used as therapeutic agents instead of murine antibodies to avoid the occurrence of

[0009] Antibodies can bind to antigens through their variable regions. Once an antibody binds to an antigen, it targets

[0010] This can be achieved by using antibody fragments lacking the Fc region (e.g., Fab, F(ab')2, or single-chain

[0011] Monoclonal antibodies against human α4 bind to three functionally distinct epitopes, A and B Summary of the Invention

[0012] The present invention relates to anti-VLA-4 antibodies and binding fragments thereof comprising germline variable region frameworks,

[0013] The antibody may also contain a modified Fc region that alters or reduces

[0014] The antibodies may improve existing

[0015] Thus, the antibodies disclosed herein may provide several advantages, including but not limited to the following:

[0016] - Provides inclusion stabilization suitable as a therapeutic agent due to its reduced effector function

[0017] - providing a composition suitable as a therapeutic agent due to its reduced effector function comprising a composition derived from

[0018] - An efficient method for generating stabilized Fc polypeptides with minimal changes to the polypeptide

[0019] - Enhance the stability of Fc polypeptides while avoiding any immunogenicity and / or effector function

[0020] - Methods for enhancing the tunability, manufacturing and / or long-term stability of Fc polypeptides; and

[0021] - A method of treating a subject in need of treatment with the stabilized Fc polypeptides of the invention.

[0022] In one embodiment, the present invention provides an anti-α4 antibody VH chain having

[0023] In one embodiment, the germline sequence is Figure 1 The humans depicted in

[0024] In one embodiment, at least one of the complementarity determining regions (CDRs) of the variable domain or

[0025] Thus, in one embodiment, the variable heavy chain (VH) framework has a

[0026] In another embodiment, at least one amino acid in the FR1 region of VH and less

[0027] In another embodiment, at least one amino acid in the FR2 region of VH and less

[0028] In another embodiment, at least one amino acid in FR3 of the VH chain and less

[0029] In certain embodiments, the VH chain of the antibody has SEQ ID NO: 3, SEQ

[0030] In one aspect, the present invention provides an anti-VLA-4 VL chain having a

[0031] In another embodiment, the germline sequence is Figure 2 IGKV4-1 as described in

[0032] In one embodiment, the sequence is Figure 2 AAH7035.1 as described in

[0033] In one embodiment, at least one of the complementarity determining regions (CDRs) of the variable domain or

[0034] In another embodiment, at least one amino acid in FR1 of the VL chain and less

[0035] In another embodiment, at least one amino acid in FR2 of the VL chain and less

[0036] In another embodiment, at least one amino acid in FR3 of the VL chain and less

[0037] In other embodiments, the VL chain of the antibody has SEQ ID NO: 8, SEQ

[0038] In one embodiment, the VH chain of the antibody has the sequence of SEQ ID NO: 4.

[0039] In one embodiment, the CDRs of the VH and VL acceptor framework sequences are selected

[0040] In another aspect, the present invention provides an antibody or antigen-binding fragment thereof comprising:

[0041] -Anti-VLA-4 VL chains described herein, e.g., with VL from a donor anti-VLA-4

[0042] -Anti-VLA-4 VH chains described herein, e.g., with VH from a donor anti-VLA-4

[0043] In one embodiment, the antibody binds to one or both of α4β1 and α4β7.

[0044] In another aspect, the VL or VH chains or antibodies or fragments thereof described herein are

[0045] In another aspect, the present invention provides a recombinant anti-α4 antibody or an α4-binding fragment thereof,

[0046] In some embodiments, the constant heavy chain of human IgG1 comprises at least two mutations,

[0047] In some embodiments, the constant heavy chain of human IgG1 comprises at least three mutations,

[0048] In some embodiments, the constant heavy chain of human IgG1 comprises the following, consisting of

[0049] In some embodiments, the constant heavy chain of human IgG1 comprises the following mutations:

[0050] In another aspect, the present invention provides a recombinant anti-α4 antibody or an α4-binding fragment thereof,

[0051] In some embodiments, the constant heavy chain of human IgG4 comprises at least two mutations,

[0052] In some embodiments, the constant heavy chain of human IgG4 comprises the following, consisting of

[0053] In some embodiments, the constant heavy chain of human IgG4 comprises the following, consisting of

[0054] Note that the C-terminal lysine residue (at position 478 according to the Kabat numbering scheme) is usually

[0055] In some embodiments, the constant heavy chain of human IgG1 without mutations or substitutions has

[0056] In some embodiments, the constant heavy chain of a human IgG4 without mutations or substitutions has

[0057] In another aspect, the present invention provides a vector comprising a vector encoding the

[0058] In another aspect, the present invention provides a vector comprising a vector encoding the

[0059] In another aspect, the present invention provides a vector comprising a vector encoding the

[0060] In another aspect, the present invention provides a host cell comprising the

[0061] In one aspect, the present invention provides a method for producing a recombinant anti-α4 antibody or an α4 binding fragment thereof.

[0062] In one aspect, the present invention provides a method for producing a recombinant anti-α4 antibody or an α4 binding fragment thereof.

[0063] In another aspect, the present invention provides a method for treating a protein expressed by an α4 integrin, such as α4β1 (VLA-4).

[0064] In another aspect, the present invention provides a method for treating a patient by administering an α4-binding antibody or an antibody

[0065] In another embodiment, the patient suffers from an inflammatory disorder, such as multiple sclerosis.

[0066] In certain embodiments, a therapeutically effective amount of an α4-binding antibody is administered to the patient.

[0067] In another embodiment, the method further comprises administering to the patient a second therapeutic

[0068] In one embodiment, the patient is administered a humanized antibody described herein.

[0069] In one embodiment, a composition comprising an α4 binding antibody is prepared according to a protocol, e.g.

[0070] In one embodiment, the clearance rate of the patient's previously administered anti-α4 antibody can be determined based on the patient's

[0071] In one embodiment, the composition is administered continuously, for example, over a period of more than 30 minutes.

[0072] In some embodiments, the antibody and the second agent are each administered in a manner similar to that used in a single

[0073] Another aspect provided herein is a method of evaluating a patient.

[0074] In another aspect, a method of distributing a composition described herein is provided.

[0075] In another aspect, the present invention provides a package containing at least two unit doses of

[0076] In another aspect, the invention comprises instructing a recipient to administer a formulation comprising an α4-binding antibody.

[0077] In one embodiment, the stabilized polypeptide comprises a chimeric Fc region, wherein the stabilized

[0078] In one embodiment, the Fc region is a glycosylated Fc region.

[0079] In one embodiment, the Fc region is an aglycosylated Fc region.

[0080] In one embodiment, the Fc region is at position 297 (EU numbering) in the Fc region,

[0081] In one embodiment, the chimeric Fc region comprises an IgG from the IgG4 isotype.

[0082] In one embodiment, the chimeric Fc region comprises an IgG from the IgG4 isotype.

[0083] In one embodiment, the IgG antibody is a human antibody.

[0084] In one embodiment, the aglycosylated Fc region comprises a chimeric hinge domain.

[0085] In one embodiment, the chimeric hinge domain comprises at amino acid position 228

[0086] In one embodiment, the antibody comprises a sequence having SEQ ID NO: 4.

[0087] In one embodiment, the antibody comprises a sequence having SEQ ID NO: 80.

[0088] In one embodiment, the antibody comprises a heavy chain of SEQ ID NO: 86, i.e.

[0089] In one embodiment, the antibody comprises a heavy chain of SEQ ID NO: 87, i.e.

[0090] In one embodiment, the antibody comprises a heavy chain of SEQ ID NO: 88, i.e.

[0091] In one embodiment, the antibody comprises the heavy chain of SEQ ID NO: 89, i.e.

[0092] In one embodiment, the antibody comprises a heavy chain of SEQ ID NO: 90, i.e.

[0093] In some therapeutic antibodies, such as those with an IgG4 constant region, perturbations may

[0094] Other features and advantages of the present invention will become apparent from the following detailed description and claims. BRIEF DESCRIPTION OF THE DRAWINGS

[0095] This patent or application file contains at least one drawing executed in color.

[0096] Figure 1 HP1 / 2 heavy chain (SEQ ID NO: 1) to human heavy germline IGHV1-f (SEQ

[0097] Figure 2 HP1 / 2 light chain (SEQ ID NO: 6) is shown to be the germline IGKV4-1 antibody sequence

[0098] Figure 3 is a graph depicting the results of ELISA assays.

[0099] Figure 4 is a graph depicting the results of ELISA assays.

[0100] Figure 5 The amino acid sequence of IgG4 Fc (hinge+CH2+CH3 domains) (SEQ ID

[0101] Figure 6 Flow cytometry analysis of HuHP1 / 2 binding to various tumor cell lines

[0102] 7A to 7C The study describes the effects of HuHP1 / 2 on AML cell lines and fibronectin.

[0103] Figures 8A to 8C Compositional characterization of HuHP1 / 2 effects on MM cell lines and fibronectin

[0104] Figures 9A to 9C Compositional characterization of HuHP1 / 2 effects on CLL cell lines and fibronectin

[0105] Figure 10 Describe the structure of a typical antigen-binding polypeptide (IgG antibody) and the antigen binding of antibodies

[0106] 11A to 11D Depicted from the IgG1 X-ray crystal structure (pdb code 1hzh)

[0107] FIG12 depicts the turbidity of exemplary IgG Fc constructs of the invention after stirring (Panel A)

[0108] Figure 13 Plotting the time course of IgG Fc constructs maintained at low pH (pH 3.1)

[0109] Figure 14 Depicts the present invention as measured by solution affinity surface plasmon resonance

[0110] FIG15 depicts a graph used to calculate binding of exemplary IgG1 and IgG4 Fc constructs of the invention.

[0111] Figure 16 depicts IgG1 T318K (Kabat numbering) (T299K, EU numbering) highlighted

[0112] Figure 17 Depicts exemplary IgG4 Fc constructs incorporating the T299K mutation compared to

[0113] Figure 18 Depicts exemplary IgG1 and IgG4 Fc constructs used to evaluate the effects of the present invention on complement

[0114] Figure 19, Panels A and B, respectively, show the methods used to evaluate the binding of various Fc constructs to CD64

[0115] Figure 20, Panel A, shows the results for evaluating T318X (Kabat numbering) (T299X, EU code

[0116] Figure 21, Panel A, shows a titration curve for evaluating the binding of constructs to CD64,

[0117] Figure 22A Includes HP1 / 2 hG4P agly (N297Q, EU numbering) G1κ light chain (H1L3)

[0118] Figure 22B Includes HP1 / 2 hG4P agly (N297Q, EU numbering) G1 heavy chain (H1L3)

[0119] Figure 23A Includes HP1 / 2 hG4P agly (N297Q, EU numbering) G1κ light chain

[0120] Figure 23B comprising a mature light chain having SEQ ID NO: 81 and a mature light chain having SEQ ID NO: 80

[0121] Figure 24A mature light chain (HP1 / 2 hG4P agly

[0122] Figure 25 The mature light chain (HP1 / 2 hG4P agly

[0123] Figure 26 The mature light chain (HP1 / 2 hG4P) having SEQ ID NO: 81 is shown.

[0124] Figure 27 The mature light chain (HP1 / 2 hG4P) having SEQ ID NO: 81 is shown.

[0125] Figures 28 to 30 The mature light chain (HP1 / 2 hG4P) having SEQ ID NO: 81 is shown.

[0126] Figure 31 The results of SDS-PAGE analysis of HP1 / 2 samples under non-reducing conditions are shown.

[0127] Figure 32A The SEC analysis results of HP1 / 2 samples are shown.

[0128] Figure 32B HP1 / 2 hG4P agly (N297Q, EU numbering) G1 H1L3, HP1 / 2

[0129] Figure 33a and Figure 33b Humanized HP1 / 2H1 / L3 huIgG4P agly

[0130] Figure 34 A single intravenous bolus of 3 mg / kg HP1 / 2H1 / L3 huIgG4P was shown to

[0131] Figure 35 A single intravenous bolus of 3 mg / kg HP1 / 2H1 / L3 huIgG4P was shown to

[0132] Figure 36 The results show that the human (human 1 and human 2) and cynomolgus monkey (cynomolgus monkey 1 and cynomolgus monkey

[0133] Figures 37A to 37D A single intravenous dose of natalizumab was administered

[0134] Figure 38 Provided are depictions of the administration of a specific dose of HP1 / 2 (referred to as HP12 in the figure, hollow DETAILED DESCRIPTION

[0135] Antibodies against VLA-4 have been shown to be useful in treating diseases.

[0136] Certain antibodies of the invention disclosed herein have demonstrated novel designed humanized α4 binding

[0137] The antibodies also have, for example, one or more stabilizing

[0138] For a clear understanding of the present specification and claims, the following definitions are conveniently provided below.

[0139] definition

[0140] As used herein, the term "effector function" refers to the ability of the Fc region or a portion thereof to bind to the immune system.

[0141] Other antigen-dependent effector functions are caused by antibodies binding to certain molecules on cells via their Fc regions.

[0142] As used herein, the term "antigen-independent effector function" refers to the

[0143] Unlike FcγRs belonging to the immunoglobulin superfamily, human FcRn is structurally similar to

[0144] As used herein, the term "half-life" refers to the in vivo biological half-life of a specific binding polypeptide.

[0145] As used herein, the term "protein" refers to a polypeptide (e.g., an Fc polypeptide) or a polypeptide comprising more than

[0146] As used herein, the terms "linked," "fused," or "fusion" are used interchangeably.

[0147] As used herein, the term "Fc region" shall be defined as the region consisting of two or more antibody heavy chains.

[0148] As used herein, the term "Fc portion" refers to the Fc portion derived from the

[0149] It should be noted that the amino acid residues in antibodies have their own numbering scheme.

[0150] In a non-limiting example, the following table illustrates the heavy chain CH1, CH2 of human IgG1.

[0155] Note that the amino acid residues in the table above are naturally occurring or typical amino acid residues in human IgG1.

[0156] Note that due to the relative abundance of human IgG molecules (e.g., IgG1, IgG2, IgG3, IgG4)

[0157] The following table shows the glutamic acid at position 216 in EU numbering (226 in Kabat numbering).

[0159] The following table shows the glutamic acid at position 216 in EU numbering (226 in Kabat numbering).

[0161] In some embodiments, the substitutions mentioned herein are in naturally occurring IgG1

[0162] The full length sequence of the naturally occurring human IgG1 heavy chain is thus used as the sequence starting at position 118 (EU

[0163] The full length sequence of the naturally occurring human IgG1 heavy chain is thus used as the sequence starting at position 118 (EU

[0164] As described herein, one of ordinary skill in the art will appreciate that the Fc portion may be

[0165] For example, the Fc portion can be derived from an immunoglobulin of the IgG1 or IgG4 isotype (e.g.,

[0166] In other embodiments, the Fc region or portion may comprise a chimeric hinge region.

[0167] The definition of "Fc region" specifically includes an "aglycosylated Fc region". As used herein, "aglycosylated Fc region"

[0168] The term "parent Fc polypeptide" includes polypeptides containing an Fc region to be stabilized (e.g., IgG

[0169] The term "mutation" or "mutating" is understood to include the

[0170] In an exemplary embodiment, the parent Fc polypeptide comprises a polypeptide derived from an effector-free Fc

[0171] The term "variant Fc polypeptide" or "Fc variant" includes Fc polypeptides derived from a parent Fc polypeptide.

[0172] A polypeptide or amino acid sequence "derived from" a specified polypeptide or protein refers to the origin of the polypeptide.

[0173] The Fc polypeptide of the present invention may comprise an amino acid sequence derived from a human immunoglobulin sequence.

[0174] Those of ordinary skill in the art will also appreciate that the Fc polypeptides of the present invention may be altered to

[0175] As used herein, the term "protein stability" refers to the stability of proteins in response to environmental conditions (e.g.

[0176] The term "amino acid" includes alanine (Ala or A); arginine (Arg or R); asparagine (Arg or R);

[0177] "Amino acid substitution" refers to the substitution of a predetermined amino acid sequence (the amino acid sequence of the starting polypeptide)

[0178] As used herein, the term "binding domain," "binding site," or "binding moiety" is

[0179] As used herein, the term "ligand binding domain" refers to a natural receptor (e.g., cell

[0180] As used herein, the term "binding free energy" or "free energy of binding" includes its

[0181] The term "specific" includes the ability to specifically bind (e.g., immune response) to a given target.

[0182] As used herein, the term "valency" refers to the potential binding affinity of a binding polypeptide or protein.

[0183] As used herein, the term "properly folded polypeptide" includes all functional components of a polypeptide.

[0184] As used herein, the term "immunoglobulin" includes an immunoglobulin having two heavy chains and two light chains.

[0185] As used herein, the term "antibody" refers to an antibody that is directed against a relevant antigen (e.g., a tumor-associated antigen).

[0186] As discussed in more detail below, the general term "antibody" includes biochemically distinguishable

[0187] Immunoglobulin light chains are classified as either kappa or lambda.

[0188] Both light and heavy chains are divided into regions of structural and functional homology.

[0189] The constant and variable regions of immunoglobulin heavy and light chains are folded into domains.

[0190] By convention, the variable and constant region domains are numbered as they are further away from the immunoglobulin

[0191] As used herein, the term "VH domain" includes the amino terminal end of an immunoglobulin heavy chain.

[0192] As used herein, the term "CH1 domain" includes the CHI domain of an immunoglobulin heavy chain, e.g.,

[0193] As used herein, the term "hinge region" includes the region that joins the CH1 domain to the CH2 junction.

[0194] As used herein, the term "CH2 domain" includes, for example, a CH2 domain extending from about EU position 231.

[0195] As used herein, the term "CH3 domain" includes the CH2 domain extending from the N-terminus.

[0196] As used herein, the term "CL domain" includes a portion of an immunoglobulin light chain, e.g.,

[0197] As indicated above, the variable regions of an antibody allow it to selectively recognize and thus specifically

[0198] As used herein, the term "antigen binding site" includes any site that binds to an antigen (e.g., a cell surface antigen)

[0199] As used herein, the term "CDR" or "complementarity determining region" refers to the complementarity determining regions between heavy and light chains.

[0202] 1 Residue numbering follows the nomenclature of Kabat et al., supra.

[0203] 2 The residue numbering follows the nomenclature of Chothia et al., supra

[0204] 3 Residue numbering follows the nomenclature of MacCallum et al., supra

[0205] As used herein, the term "framework region" or "FR region" includes the regions that are part of the variable region.

[0206] In naturally occurring antibodies, the six CDRs present on each monomeric antibody are short, non

[0207] In certain embodiments, the binding polypeptides of the invention comprise at least two antigen-binding

[0208] The term "antibody variant" or "modified antibody" includes antibodies that do not exist in nature and

[0209] As used herein, the term "scFv molecule" includes a light chain variable domain (VL) or its

[0210] As used herein, "scFv linker" refers to a linker inserted between the VL and VH structures of a scFv.

[0211] As used herein, the term "gly-ser polypeptide linker" refers to a polypeptide consisting of glycine and serine residues.

[0212] As used herein, the term "native cysteine" shall refer to a specific cysteine ​​naturally occurring in a polypeptide.

[0213] As used herein, the term "disulfide bond" includes a covalent bond formed between two sulfur atoms.

[0214] As used herein, the term "bound cysteine" shall refer to a cysteine ​​residue within a polypeptide that is the same or different from the

[0215] As used herein, the term "free cysteine" refers to a substantially free cysteine ​​residue within a polypeptide sequence.

[0216] The term "thiol-modifying agent" shall refer to a thiol-modifying agent that selectively binds to a binding polypeptide (e.g.,

[0217] The term "functional moiety" includes a moiety that, in some embodiments, adds a desired functionality to a

[0218] The term "spacer moiety" is a non-proteinaceous moiety designed to introduce a spacer into a molecule.

[0219] The term "PEGylation moiety" or "PEG moiety" includes polyalkylene glycol compounds or derivatives thereof.

[0220] As used herein, the term "drug moiety" includes anti-inflammatory agents, anti-cancer agents, anti-infective agents

[0221] As used herein, the term "prodrug" refers to a precursor or derivative form of a pharmaceutically active agent.

[0222] Affinity resins are capable of binding affinity domains with high affinity, thus facilitating the separation of

[0223] It will be understood by those skilled in the art that if the antibodies described herein are encoded

[0224] For the purposes of the present invention, a variety of expression vector systems can be used. For example, one type

[0225] The term "host cell" refers to a cell that has been constructed using recombinant DNA techniques and encodes at least

[0226] In addition to prokaryotes, eukaryotic microorganisms can also be used.

[0227] In vitro production allows for scaling up to produce large quantities of the desired altered binding protein of the present invention.

[0228] As used herein, the phrase "a subject who would benefit from administration of a binding polypeptide" includes a subject who would benefit from administration of a binding polypeptide.

[0229] The term "pegylated," "polyethylene glycol," or "PEG" includes polyalkylene glycol compounds or

[0230] I. Variable Region

[0231] The present invention provides α4 binding antibodies and fragments thereof, wherein the variable light chain (VL) and the variable heavy chain (VL)

[0232] Murine monoclonal antibody (mAb) HP1 / 2 is a member of the B1 subclass of α4 mAbs and

[0233] mAbs targeting α4 integrin are effective in infiltrating lymphocytes, eosinophils, and monocytes.

[0234] Produced in Balb / c mice injected with the JM (immature T-cell leukemia) cell line

[0235] The α4 binding antibody or fragment thereof may comprise a sequence having SEQ ID NO: 8, 9, 10 or 11.

[0236] In certain embodiments, the α4-binding antibody comprises a fragment having SEQ ID NO: 11

[0237] The α4-binding antibodies may also comprise a variant Fc region as discussed in more detail herein.

[0238] II. Parent Fc Polypeptide

[0239] Variant Fc polypeptides may be derived from parent or starting Fc polypeptides known in the art.

[0240] In certain embodiments, the Fc polypeptides of the invention comprise a single Fc portion of an Fc region.

[0241] In certain embodiments, the polypeptides of the present invention may comprise polypeptides having the same or substantially the same

[0242] In one embodiment, a binding polypeptide of the invention may comprise two or more components.

[0243] Parent Fc polypeptides can be assembled together or with other polypeptides to form multimeric Fc polypeptides or

[0244] In another embodiment, the Fc polypeptide of the invention comprises a dimeric Fc region (forming two

[0245] A. Fc part

[0246] Fc moieties suitable for use in generating the parent Fc polypeptides of the present invention can be obtained from a number of different sources.

[0247] Various Fc portion gene sequences (e.g., human constant region gene sequences) are publicly available.

[0248] For example, the polymerase chain reaction can be used and primers selected for amplification of the domain of interest can be selected.

[0249] The parent Fc polypeptide of the present invention may comprise a single Fc portion or multiple Fc portions.

[0250] In certain embodiments, a parent Fc polypeptide comprises at least one polypeptide derived from one or more

[0251] In another embodiment, the parent Fc polypeptide comprises at least one Fc portion, said

[0252] The constant region domains or parts thereof constituting the Fc portion may be derived from different immunoglobulins.

[0253] As described herein, one of ordinary skill in the art will understand that the parent Fc portion

[0254] One or more amino acid substitutions may be located within the Fc portion and are referred to as "corresponding to" the Fc region of an antibody.

[0255] In one embodiment, the substitution is at an amino group located in the hinge domain or a portion thereof.

[0256] In certain embodiments, the parent Fc polypeptide comprises more than one amino acid substitution.

[0257] In certain embodiments, the substitutions alter the expression of a polypeptide in an Fc region comprising a wild-type Fc portion.

[0258] The parent Fc polypeptide may be modified with substitutions known in the art to alter effector function.

[0259] In some embodiments, a parent Fc polypeptide may be included in a "15" corresponding to the Fc portion.

[0260] In another embodiment, the parent Fc polypeptide comprises an Fc region comprising

[0261] In certain embodiments, the parent Fc polypeptide comprises an amino acid substitution to the Fc portion,

[0262] As used herein, the term 15A FcRn "contact region" includes the wild-type full-length Fc portion

[0263] B. No effector Fc peptide

[0264] In certain embodiments, the parent Fc polypeptide is a polypeptide having altered or reduced effector function.

[0265] Fc polypeptides with reduced FcγR binding affinity are expected to have reduced effector function, and

[0266] Exemplary amino acid substitutions that alter FcγR or complement binding activity are disclosed in the International PCT

[0267] In certain exemplary embodiments, the effector function of a parent "effector-less" polypeptide may be

[0268] In certain embodiments, the aglycosylated Fc region is partially aglycosylated or hemiglycosylated.

[0269] The aglycosylated Fc region of the "effector-free" polypeptide may be of any IgG isotype (e.g.,

[0270] In certain exemplary embodiments, an "effector-less" parent Fc polypeptide comprises a polypeptide derived from

[0271] In certain embodiments, the reduced effector function of an "effector-less" Fc polypeptide is associated with

[0272] In one embodiment of the invention, the stabilized Fc polypeptide comprises a single chain Fc region.

[0273] III. Variant Fc Polypeptides with Stabilized Fc Regions

[0274] In certain aspects, the present invention provides a method comprising any of the parent Fc

[0275] In certain embodiments, a variant Fc polypeptide comprises an Fc region (Fc

[0276] These variants necessarily have less than 100% sequence identity or similarity to the starting polypeptide.

[0277] In certain embodiments, the variant Fc polypeptides of the present invention are stabilized Fc polypeptides.

[0278] In certain exemplary embodiments, the variant Fc polypeptides of the present invention are those described above.

[0279] In some embodiments, the stabilized Fc polypeptides of the invention are compared to variant Fc polypeptides.

[0280] The thermal stability of variant Fc polypeptides can be assessed, for example, using any of the methods described below.

[0281] In another embodiment, the stabilized Fc polypeptide has a thermal challenge assay greater than

[0282] In certain embodiments, the stabilized Fc molecules of the invention have Tm values ​​greater than about

[0283] In certain embodiments, the variant Fc polypeptides of the present invention are different from the parent Fc

[0284] In other embodiments, the stabilized Fc polypeptide of the present invention and the parent from which it is derived

[0285] In certain embodiments, the stabilized Fc polypeptides of the invention are similar to their parent Fc polypeptides.

[0286] In an exemplary embodiment, the stabilized Fc polypeptide of the invention is expressed in a host cell, e.g.

[0287] In other embodiments, the stabilized Fc polypeptides of the invention are used in large-scale (e.g., industrial)

[0288] (i) Stabilizing Fc Amino Acids

[0289] In certain embodiments, the stabilized Fc polypeptides of the present invention comprise

[0290] (ii) Exemplary stabilized Fc moieties

[0291] Throughout this application, in the Examples and in the Sequence Listing, exemplary stable

[0292] In certain exemplary embodiments, the stabilized Fc polypeptide of the invention comprises

[0293] Table 1.1: Stabilized IgG4 Fc fraction

[0299] In certain exemplary embodiments, the stabilized Fc polypeptides of the invention comprise

[0300] Table 1.2: Stabilized chimeric Fc moieties

[0303] In other exemplary embodiments, the stabilized Fc polypeptides of the invention comprise

[0304] Table 1.3: Stabilized aglycosylated IgG1 Fc fraction

[0307] IV. Methods for Stabilizing Variant Fc Polypeptides

[0308] In certain aspects, the present invention relates to a method for making a glycosylated Fc region (e.g., aglycosylated Fc

[0309] In one embodiment, the starting Fc region is an IgG1 Fc region.

[0310] In some embodiments, the Fc region of an antibody (or fragment thereof) as described herein has

[0311] In one embodiment, the amino acid position selected for mutation is in the starting IgG molecule

[0312] Exemplary amino acid positions include amino acid positions 240, 255,

[0313] In certain embodiments, the Fc region is an IgG1 Fc region.

[0314] In one embodiment, the mutation reduces the size of the amino acid side chain at the amino acid position.

[0315] In one embodiment, the mutation is a substitution with alanine (A).

[0316] In one embodiment, the mutation comprises the following Table 5.1, Table 5.2, Table 5.3 and / or Table

[0317] In certain embodiments, the mutations comprise one or more selected from the group consisting of

[0318] In another embodiment, the mutation comprises two or more substitutions (e.g., 2,

[0319] In another aspect, the present invention relates to a method for producing a stabilized Fc region comprising a stabilized

[0320] In another embodiment, the therapeutic antibody can eliminate the perturbation or reduce the antibody's ability to perturb the perturbation.

[0321] In some embodiments, as a chimera between human IgG1 and human IgG4 antibodies

[0322] V. Methods for Assessing Protein Stability

[0323] The stability of the compositions of the present invention can be analyzed using methods known in the art.

[0324] In certain embodiments, the stability of an Fc polypeptide is compared to the stability of a suitable control.

[0325] In one embodiment, these parameters are measured following expression in mammalian cells.

[0326] A. Thermal stability

[0327] Many non-limiting biophysical or biochemical techniques known in the art may be used.

[0328] Another exemplary analytical spectroscopy method is circular dichroism (CD) spectroscopy. CD spectroscopy measures

[0329] Another exemplary analytical spectroscopy method for measuring thermal stability is fluorescence emission spectroscopy.

[0330] In other embodiments, the thermal stability of the compositions of the present invention is measured biochemically.

[0331] In one embodiment, this assay can be performed in a high throughput format.

[0332] In certain embodiments, by using any of the above techniques (e.g., analytical spectroscopy techniques)

[0333] In other embodiments, the present invention is measured by using analytical calorimetric techniques (e.g., DSC).

[0334] In other embodiments, one or more of the above biochemical assays (e.g.

[0335] B. Aggregation %

[0336] In certain embodiments, the aggregation tendency of a composition of the invention is determined by measuring its

[0337] In some embodiments, SEC is combined with tandem light scattering (e.g., classical or dynamic light scattering)

[0338] In one non-limiting embodiment, by measuring protein aggregation within a protein sample

[0339] C. Yield %

[0340] In other embodiments, the protein is expressed (e.g., recombinantly) by measuring the

[0341] D. Loss %

[0342] In other embodiments, by monitoring the temperature within a certain range (e.g., -80°C to

[0343] E. Protein hydrolysis%

[0344] In other embodiments, proteolysis is determined by measuring the amount of proteolysis that occurs after storage under standard conditions.

[0345] F. Binding affinity

[0346] In other embodiments, the target binding affinity of the compositions of the invention can be determined.

[0347] G. Other Combination Studies

[0348] In other embodiments, the denatured binding molecules can be obtained by

[0349] VI. Stabilized Binding Polypeptides Comprising Stabilized Fc Regions

[0350] In one embodiment, a polypeptide of the invention comprises a CH1 binding site from an IgG4 antibody.

[0351] In one embodiment, the Fc region of the polypeptide of the invention is a single chain (scFc).

[0352] VII. Stabilized Fc-containing polypeptides comprising functional moieties

[0353] The variant Fc-containing polypeptides of the present invention may be further modified to provide the desired effect. For example

[0354] Examples of suitable functional moieties include, but are not limited to, blocking moieties, detectable moieties, diagnostic moieties,

[0355] Pegylated antibodies and antibody fragments are generally useful therapeutically by administering the

[0356] Examples of diagnostic moieties suitable for use in the methods and polypeptides of the invention include those suitable for revealing

[0357] Examples of therapeutic moieties suitable for use with the methods and polypeptides of the invention include, for example, anti-inflammatory agents,

[0358] Exemplary therapeutic agents include those that induce multiple strand breaks in nuclear DNA and are therefore suitable for

[0359] Exemplary therapeutic agents also include cytotoxic agents, such as cytostatic agents (e.g., alkylating

[0360] Exemplary therapeutic agents also include alkylating agents, such as anthracyclines (e.g., adriamycin

[0361] Exemplary therapeutic agents also include cytotoxic nucleosides, such as adenosine, cytarabine,

[0362] Exemplary therapeutic agents also include enzyme inhibitors such as S(+)-camptothecin, curcumin, (-)-

[0363] Exemplary therapeutic agents also include cytotoxic agents such as pteridines, diacetylenes, and phenazine.

[0364] Other cytotoxins compatible with the teachings herein include auristatins

[0365] For the above functional parts, small molecules, nucleic acids, polymers, peptides, proteins,

[0366] VIII. Pharmaceutical Compositions

[0367] α4 binding agents (e.g., VLA-4 binding antibodies with stabilized Fc regions) can be formulated as

[0368] "Pharmaceutically acceptable salts" are salts that retain the desired biological activity of the parent compound and

[0369] The antibody compositions described herein can be formulated according to methods known in the art.

[0370] In one embodiment, the α4 antibody can be mixed with, for example, sodium chloride, dihydrogen phosphate heptahydrate,

[0371] Pharmaceutical compositions may also be in a variety of other forms. These include, for example, liquid, semi-solid and

[0372] These compositions may be administered by parenteral means (e.g., intravenously, subcutaneously, intraperitoneally, or

[0373] Pharmaceutical compositions typically must be sterile and stable under the conditions of manufacture and storage.

[0374] The composition can be formulated into a solution, microemulsion, dispersion, liposome or a high-drug

[0375] IX. Administration

[0376] α4 binding antibodies with stabilized Fc regions can be administered to a subject by a variety of methods.

[0377] In one embodiment, the antibody is administered in 50 mg, 60 mg, 70 mg, 75 mg,

[0378] Anti-α4 antibodies with stabilized Fc regions may also be present at between about 1 and 10 mg / kg, for example

[0379] The dosage may be adjusted based on the clearance rate of the patient's previously administered anti-α4 antibody.

[0380] The dose can also be selected to reduce or avoid the production of antibodies against the α4 binding antibody to achieve

[0381] In certain embodiments, the active agent may be formulated with a carrier that will prevent rapid release of the compound.

[0382] The pharmaceutical composition can be administered using a medical device. For example, the pharmaceutical composition can be administered using a needle-free

[0383] The present invention also provides a device for administering a first agent and a second agent.

[0384] Dosage regimens are adjusted to provide the desired response, eg, a therapeutic response or a combined therapeutic effect.

[0385] As used herein, dosage unit form or "fixed dose" refers to a

[0386] A pharmaceutical composition may include a "therapeutically effective amount" of an agent described herein.

[0387] X. Devices and Kits

[0388] The formulations containing the antibodies described herein can be administered using a medical device.

[0389] For example, the pharmaceutical composition may be delivered via a transdermal delivery device, such as a syringe,

[0390] The pharmaceutical composition can be administered using a medical device. For example, the pharmaceutical composition can be administered using a needle-free

[0391] The present invention also provides a method for administering a first agent and a second agent (e.g., an antibody and a second

[0392] The α4 binding antibody may be provided in a kit. In one embodiment, the reagent

[0393] The informational material of the kit is not limited in its form. In one embodiment,

[0394] In addition to the agent, the composition in the kit may include other ingredients, such as solvents or buffers.

[0395] The kit may include one or more compositions containing the agent.

[0396] The kit optionally includes a device suitable for administering the composition, such as a syringe or other suitable

[0397] XI. Oncology

[0398] The α4-binding antibodies and methods described herein can be used to treat cancer, including solid

[0399] Provided are methods for using a method comprising an α4 binding antibody, such as an anti-VLA-4 antibody described herein.

[0400] Blood counts can be analyzed by, for example, light microscopy, which can be used to identify malignant cells.

[0401] α4 binding antibodies (e.g., humanized anti-VLA-4 antibodies, such as HuHP1 / 2, H1L0,

[0402] All AML subtypes are amenable to treatment with VLA-4 binding antibodies.

[0403] Risk factors for AML include the presence of certain genetic conditions, such as Down syndrome

[0404] Other risk factors for AML include chemotherapy or radiation used to treat different cancers.

[0405] Other cancers suitable for treatment with α4-binding antibodies include solid tumors such as sarcomas and

[0406] XII. Other diseases

[0407] The formulations and methods described herein may also be used to treat other inflammatory, immune, or

[0408] The formulations and methods described herein can also be used to treat neurological disorders, such as

[0409] The formulations and methods described herein can also be used to treat patients who have undergone transplantation, such as kidney,

[0410] XIII. Multiple sclerosis

[0411] Formulations containing the α4-binding antibodies described herein can be used to treat inflammatory diseases.

[0412] A diagnosis of clinically definite MS can be established as defined by the MS Diagnosis Workshop.

[0413] Exacerbations are defined as the onset of new symptoms attributable to MS accompanied by appropriate new neurological abnormalities.

[0414] For any of these measures, if there was no difference in progression between the treatment group and the placebo group,

[0415] Administration of the first dose and optionally

[0416] Clinical outcome measures included relapse rate at one and two-year intervals, and change in EDSS.

[0417] MRI can be used to measure active lesions using gadolinium-DTPA enhanced imaging (McDonald

[0418] Exemplary diseases associated with multiple sclerosis that can be treated with the methods described herein include

[0419] Each case of MS displays one of several patterns of presentation and subsequent course. Most commonly, MS

[0420] Thus, the relapsing form of MS (or simply relapsing MS)

[0421] A small number of patients experience aggressive MS, defined as a rapid and uninterrupted decline that causes the disease

[0422] Administration of the anti-α4 antibodies provided herein can effectively alleviate one or more symptoms of MS.

[0423] Animal models can be used to evaluate the potential of

[0424] XIV. Epilepsy

[0425] Formulations containing the α4 binding antibodies described herein are useful for treating epilepsy.

[0426] Epileptic seizures are caused by abnormal firing of neurons that can be detected by electroencephalography or clinical methods.

[0427] Prior to this invention, the common treatment for epilepsy patients was anti-epileptic drugs

[0428] To develop drugs that can improve seizure control or eliminate seizures in drug-resistant epilepsy

[0429] The formulations disclosed herein can be used to treat epilepsy. For example,

[0430] XV. Antibody Production

[0431] Recombinant proteins that bind to α4 can be generated by in vivo or in vitro methods, such as phage display.

[0432] EP 239 400 (Winter et al.) describes the use of complementarity determining regions of a species

[0433] The anti-α4 antibodies or antibody fragments described herein can recognize and specifically bind to

[0434] In some embodiments, the antibodies provided herein can bind to cells (e.g., lymphocytes

[0435] Exemplary α4-binding antibodies have one or more CDRs, e.g., those disclosed herein.

[0436] In one embodiment, the amino acid sequence of the HC and / or LC variable domain sequence is the same as that of the

[0437] The amino acid sequences of the HC and LC variable domain sequences can be determined by binding to the present invention under high stringency conditions.

[0438] "Homology" or "sequence identity" (as such term is used in the

[0439] As used herein, the term "hybridizes under high stringency conditions" describes a hybridization and washing process.

[0440] XVI. Antibody Production

[0441] Antibodies can be produced in prokaryotic and eukaryotic cells. In one embodiment,

[0442] In one embodiment, antibodies, particularly full-length antibodies, are produced in mammalian cells.

[0443] In addition to nucleic acid sequences encoding immunoglobulin domains, recombinant expression vectors may also carry

[0444] In an example of a method for recombinantly expressing an antibody (e.g., a full-length antibody or an antigen-binding portion thereof)

[0445] Antibodies may also include modifications, such as those that alter Fc function, such as to reduce or remove

[0446] In another example, the human IgG1 constant region may be modified at one or more residues, e.g.

[0447] For some antibodies that include an Fc domain, an antibody production system can be designed to synthesize the Fc

[0448] Other suitable Fc domain modifications include those described in WO2004 / 029207

[0449] Antibodies can also be produced by transgenic animals. For example, U.S. Pat. No. 5,849,992

[0450] Antibodies may be modified, for example, to stabilize and / or maintain their activity in circulation, for example in the blood.

[0451] For example, a VLA-4 binding antibody can be associated with a polymer, such as a substantially non-antigenic

[0452] For example, a VLA-4 binding antibody can be conjugated to a water-soluble polymer, such as a hydrophilic

[0453] XVII. Exemplary Second Doses

[0454] In some cases, the formulations described herein, e.g., containing an α4-binding antibody

[0455] In one embodiment, the α4 binding antibody and the second agent are provided as a co-formulation.

[0456] Generally, the antibody and the second agent are each administered in multiple doses separated by time.

[0457] In some embodiments, the antibody and the second agent are each administered in a manner similar to that used in a single

[0458] Non-limiting examples of a second agent for use in combination with an α4-binding antibody for the treatment of multiple sclerosis

[0459] Interferons, such as human interferon beta-1a (e.g.

[0460] ■ Glatiramer acetate (also known as copolymer 1, Cop-1; COPAXONE TM ;Teva

[0461] ■

[0462] ■Mitoxantrone (mixtoxantrone)

[0463] Remyelinating agents, such as opicinumab;

[0464] Chemotherapeutic agents, such as clabribine

[0465] ■Corticosteroids, such as methylprednisolone (

[0466] ■Immunoglobulins, e.g.

[0467] Statins; and

[0468] ■TNF antagonists.

[0469] Glatiramer acetate is a non-steroidal anti-inflammatory drug consisting of the amino acids glutamic acid, lysine, alanine, and tyrosine.

[0470] Additional second doses include other human cytokines or growth factors, such as TNF, LT,

[0471] Other exemplary antibodies include antibodies that provide the activity of the agents described herein, e.g.

[0472] Other additional exemplary second agents include: FK506, rapamycin, mycophenolic acid, leflunomide

[0473] In some embodiments, the second dose may be used to treat one or more symptoms of MS or

[0474] Examples of TNF antagonists include chimeric, human,

[0475] In addition to the second dose, it is possible to deliver other doses to the subject.

[0476] Unless otherwise defined, all technical and scientific terms used herein have

[0477] Example

[0478] Unless otherwise indicated, all amino acid numbering in these examples uses the EU

[0479] Example 1. Variant anti-VLA-4 antibodies are more potent than humanized HP1 / 2.

[0480] For the VL chain, use the germline framework IGKV4-1 (for designing L1 and L2) or the germline framework

[0481] Heavy chain variants

[0482] The sequences of the three variants of the heavy chain are shown in FIG as design H0, design H1 and design H2.

[0483] Light chain variants

[0484] The four variant sequences of the light chain are designed as L0, L1, L2 and L3.

[0485] The results of the competitive ELISA assay are shown in Tables 2 and Figure 3In this experiment, α4β1

[0486] Table 2. Competition assay by ELISA

[0487] mAbs IC50 nM Chimeric HP1 / 2 1.06 H1L0 1.87 H1L1 1.67 H1L2 0.9 H1L3 0.49 HuHP1 / 2 1.05

[0488] In Table 2, chimeric mAbs are chimeric HP1 / 2 antibodies in which the murine variable heavy chain and

[0489] Another competitive assay compared the new antibody with the humanized

[0490] Table 3. Competition assay by ELISA

[0492] Example 2. Humanized HP1 / 2 (HuHP1 / 2) binds to tumor cell lines

[0493] The binding of anti-VLA-4 antibody HuHP1 / 2 to various cell lines was tested by flow cytometry.

[0494] HuHP1 / 2 was also found to block the adhesion of AML cell lines to fibronectin (FN) and

[0495] HuHP1 / 2 was also found to block adhesion of MM cell lines to FN and VCAM1-Ig fusion proteins.

[0496] HuHP1 / 2 was also found to block adhesion of CLL cell lines to FN and VCAM1-Ig fusion proteins.

[0497] The binding affinity of HuHP1 / 2 to tumor cell lines was calculated from the data shown in Figures 7 to 9.

[0498] Table 4. Quantification of HuHP1 / 2 on tumor cell lines

[0500] Materials and methods used in Examples 3 to 13

[0501] Throughout Examples 3 to 13, unless otherwise stated, the following

[0502] In general, the practice of the present invention employs, unless otherwise indicated, conventional chemical techniques,

[0503] Parental antibody

[0504] To generate the stabilized antibodies disclosed herein, a gene encoding a model human antibody (e.g.

[0505] Hu 5c8 IgG4 heavy chain (EAG1807) (SEQ ID NO: 52)

[0506] QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYMYWVK QA

[0507] DSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEAL

[0508] HNHYTQKSLSLSLG

[0509] Hu 5c8 light chain (SEQ ID NO: 53)

[0510] DIVLTQSPATLSVSPGERATISCRASQRVSSSTYSYMHWYQQK

[0511] Hu 5c8 VH / CH1 domain (SEQ ID NO:54)

[0512] QVQLVQSGAEVVKPGASVKLSCKASGYIFTSYYMYWVK Q

[0513] Parent IgG4 Fc portion (SEQ ID NO: 55)

[0514] ESKYGPPCPSCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV TC

[0515] Parental IgG4 Fc portion with S228P mutation (SEQ ID NO: 56)

[0516] ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEV TC

[0517] Parental IgG4 aglycosylated Fc portion with S228P / T299A mutations (YC407)

[0518] ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV

[0519] Parent IgG1 aglycosylated Fc portion (SEQ ID NO: 58)

[0520] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV

[0521] Parental IgG4 aglycosylated Fc (EAG2412) with S228P / N297Q mutations (S

[0522] ESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCV

[0523] Parent IgG1 (SEQ ID NO: 60)

[0524] EPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEV

[0525] Example 3. Rational design of stability-enhancing IgG Fc mutations

[0526] Aglycosylated antibodies represent an important class of therapeutic agents where immune effector functions are not required.

[0527] A. Cooperative Variation and Residue Frequency Design of Effector-Free IgG: IgG4 CH2 Binding

[0528] Covariation analysis was performed using different C1 class Ig fold sequence databases as previously described.

[0529] For this study, the CH2 sequence from IgG4 was used as the query sequence and

[0530] Residue frequency analysis based on individual positions within the protein fold has been successfully used to improve

[0531] Table 5.1. Residues and rationale for stability-increasing mutations

[0535] B. Structural analysis and design for effector-free IgG

[0536] In addition to mutations designed through covariation and residue frequency analysis, intact human IgG

[0537] The interface between the CH3 domains constitutes the largest protein in the Fc domain of the IgG molecule.

[0538] Finally, one of the most commonly used mechanisms to explain the increased thermostability of thermophilic proteins

[0539] C. Design of cooperative variants of effector-free IgG: Based on other C-class Ig structures

[0540] IgG CH2 domains share many conserved residues to maintain the same structure as EU N297.

[0541] The residues that are important for possible interactions with N-linked carbohydrates are

[0542] Compilation of class C1 Ig fold sequences and structure / HMM-based characterization were performed as previously described.

[0543] Based on structural analysis, it was found that the hydrophobic residues V262 and V264 are located on the surface of the CH2 domain.

[0544] The three valine residues (262, 264 and 266) also form a unique

[0545] Based on these observations, we generated designs to investigate the effects of these positions on other amino acids.

[0546] Table 5.2. Mutations to the Aglycosyl-IgG1 CH2 Domain.

[0548] a The A299K mutation was made to interrupt the N-linked glycosylation motif, resulting in a sugar-free

[0549] b The alignment of the native sequence relative to the fully modified sequence is shown in Figure 11D middle.

[0550] D. Support mutation

[0551] To test the specificity of a particular mutation type at a given residue position, we designed a

[0552] Table 5.3. Supported mutations

[0555] E. Additional multiple mutation constructs

[0556] To reduce the potential T cell epitopes generated by peptides with the stabilizing mutation T299K

[0557] Table 5.4 Additional multiple mutation constructs

[0559] Example 4. Thermal stability of IgG Fc antibody domains produced in E. coli

[0560] The improved thermal attack test method described in U.S. Patent Application No. 11 / 725,970 was used.

[0561] pBRM012 (IgG1) and

[0562] After heat challenge, aggregated material was removed by centrifugation and analyzed by DELFIA.

[0563] Table 6.1. Delphia thermal attack assay results

[0566] Example 5. Generation of stabilized IgG Fc antibodies

[0567] A. Transient expression and purification of mutagenesis-induced, stabilized IgG Fc fragments in E. coli

[0568] The Stratagene Quik-Change Lightning mutagenesis kit was used to

[0569] Table 7.1. IgG-Fc constructs expressed and purified from E. coli

[0570] Final amino acid substitutions using EU numbering BRM013 IgG4.P S228P,T299A BRM023 S228P,T299A,T307P BRM030 S228P,T299K CR103 S228P,T299A,R409K CR104 S228P,T299A,R409M CR105 S228P,T299A,R409L CR106 S228P,T299A,R409I CR107 S228P,T299A,D399S CR108 S228P,T299A,D399N CR109 S228P,T299A,D399E CR110 S228P,T299A,V369I CR111 S228P,T299A,V379I CR112 S228P,T299A,V397I CR113 S228P,T299A,V427I CR114 S228P,T299A,V427F CR115 S228P,T299A,V240I CR116 S228P,T299A,V263I CR117 S228P,T299A,V273I CR118 S228P,T299A,V302I CR119 S228P,T299A,V323I

[0571] After PCR using primers that will introduce mutations, the DNA was restricted with Dpn I at 37°C.

[0572] Sequence-verified DNA was transformed into 3110 cells by electroporation using the EC3 protocol.

[0573] The IgG-Fc construct was purified by batch purification using Protein A Sepharose FF (GE Healthcare).

[0574] B. Mutation-induced and stabilized antibody transient expression in CHO cells, antibody purification

[0575] Stratagene Quik-Change Lightning mutagenesis kit was used to

[0576] Table 7.2. Protein production of IL cultures as measured by analytical size exclusion chromatography

[0579] After PCR using primers that will introduce mutations, the DNA was restricted with Dpn I at 37°C.

[0580] DNA from the confirmed sequence was scaled up and transformed into TOP10 E. coli

[0581] The mutant plasmid was then co-transfected with an equal amount of 5c8 VL plasmid into CHO-S cells.

[0582] Protein A Sepharose FF (GE

[0583] C. Confirmation of Protein Sequence and Post-translational Characterization of Stability-engineered Antibodies Using Mass Spectrometry

[0584] The samples were analyzed under reducing conditions.

[0585] The results confirmed the identity of all 13 samples, in which the N-terminal glutamine (Q) of the heavy chain was converted to

[0586] Table 7.3. Detection quality

[0589] It should be noted that among the antibodies described herein, post-translational modifications may vary widely.

[0590] Samples EC323, EC326 and EAG2300 contain common GOF, GIF, G2F double

[0591] All sample strands contained a -18 Da peak, which was shown to be related to the gas temperature of ESI-TOF.

[0592] Example 6. Thermal stability of aglycosylated IgG Fc antibody

[0593] Protein stability is a central issue in the development and scale-up of protein therapeutics.

[0594] The antibody was reacted with 25 mM sodium citrate, 150 mM NaCl buffer at pH 6.0.

[0595] Table 8.1. E. coli expressed IgG Fc constructs as measured by DSC

[0598] As depicted in Table 8.1, agly IgG1 and IgG4.P(S228P,T299A) Fc portions

[0599] To evaluate single mutations and combinations of multiple mutations, full-length IgG molecules were used.

[0600] Table 8.2. Melting temperatures of full-length IgG constructs as measured by DSC

[0603] As depicted in Table 8.2, the D399S mutation aggre- gates the CH3 domain in agly IgG4.P.

[0604] In IgG4.P, T299K, T307P, L309K and D399S were combined.

[0605] Mutations identified in CH2 glycosylation cooperative variation studies showed an effect on the Tm of IgG1 CH2

[0606] In conclusion, T299K, T307P, and L309K showed significant differences when used as single mutations or in combination with each other.

[0607] Example 7: Study on the stirring and pH maintenance steps of IgG Fc antibodies

[0608] It is highly desirable for protein therapeutics to have a long shelf life, the physical or chemical properties of proteins

[0609] A. Stirring stress

[0610] Agitation simulates the stresses encountered during manufacturing and processing as well as simulating actual transportation (i.e.

[0611] The construct with the highest thermostability (see Example 6) was selected for stirring studies.

[0612] When comparing the aglycosylation mutants with respect to turbidity (see Tables 9.1 and Figure 12A ),

[0613] Table 9.1: Turbidity of constructs at various time points during stirring

[0614] time 0 hours 6 hours 24 hours 48 hours EC304 0 0.232 0.584 0.89 EC323 0 0.333 0.672 1.139 EC326 0 0.088 0.316 0.595 EC331 0 0.157 0.343 0.54 YC401 0 0.51 1.406 1.49 YC402 0 0.717 1.331 1.54 YC403 0 0.221 0.675 0.892 YC404 0 0.334 0.884 0.977 YC405 0 0.885 1.94 1.841 YC406 0 0.29 0.838 0.993 YC407 0 0.772 2.5 2.709 CN578 0 0.029 0.078 0.072 IgG1 T299A 0 0.019 0.144 0.348 IgG4.P T299K 0 1.322 1.51 1.657 IgG1 299T 0 0.009 0.01 0.008 IgG4 299T 0 0.009 0.0465 0.0185

[0615] When comparing monomer % (see Tables 9.2 and Figure 12B , all mutant constructs showed

[0616] Table 9.2: % monomer of constructs at various time points during agitation

[0617] time 0 hours 6 hours 24 hours 48 hours EC304 100 96.5 90.52 87.22 EC323 100 98.16 96.29 94.37 EC326 100 98.11 95.89 93.35 EC331 100 100 100 100 YC401 96.5 90.17 73.63 71.07 YC402 96.6 89.45 85.49 80.88 YC403 95 95.382 90.03 84.75 YC404 97 95.45 83.78 73.5 YC405 92.7 87.46 76.72 72.1 YC406 95.5 94.12 83.89 74.8 YC407 97 95.88 72.3 33.4 CN578 99.73 100 100 99.3 IgG1 T299A 100 100 100 100 IgG4.P T299K 96.7 100 0 0 IgG1 299T 100 99.01 98.85 99 IgG4 299T 80.51 80.2 80.35 78.06

[0618] For IgG1 aglycosylated molecules, CN578 (aglycosylated IgG1 A299K) showed the best

[0619] In the glycosylated molecules EC304 (glycosylated IgG4.P T307P, D399S), EC323 (glycosylated

[0620] B. Low pH Maintenance Step Study

[0621] There is a great need for protein therapeutics to be manufacturable and scalable.

[0622] Table 9.3: Relative peak height of IgG Fc over time at low pH

[0623] time 0 hours 2 hours 4 hours 6 hours 24 hours EC304 100 100.74 100.53 100.18 98.82 EC323 100 99.66 99.99 60.8 53.47 EC326 100 100.83 99.8 100.16 101.27 EC331 100 99.22 99.09 100.82 97.79 IgG1299T 100 95.15 95.12 96.76 94.08 IgG1 T299A 100 100.39 100.5 100.91 99.01 IgG4.P T299A 100 101.68 103.33 54.84 52.53

[0624] For this study, EC304 (glycosylated IgG4.P T307P, D399S), EC323

[0625] Example 8. Fc receptor binding of stability-engineered IgG Fc antibodies

[0626] The effector function of the aglycosylated variant antibody of the present invention is characterized by its ability to bind

[0627] A. Solution-phase competition Biacore experiments

[0628] Binding to Fcγ receptors was analyzed using solution affinity surface plasmon resonance (ref.

[0629] Table 10.1. FcγR affinity characterization of Fc variants

[0631] IC of IgG1 control antibody in CD64 binding assay 50 9.6 μM, while IgG1

[0632] For the CD16 assay, the IgG1 control had an IC of 105 μM 50 , without glycosylation

[0633] B. C1q binding ELISA

[0634] The cells were washed with 50 μl of recombinant soluble human

[0635] After aspiration and washing as above, add 50 J of each well diluted in blocking / dilution buffer.

[0636] After aspiration and washing as above, add 50 μl / well of a 5% HCl solution diluted in blocking / dilution buffer.

[0637] After aspiration and washing as above, 100 μl of TMB substrate (420 μM TMB, containing

[0638] The experimental results showed that CN578 (IgG1 T299K) and YC406 (aglycosylated IgG4.P

[0639] Example 9. IgG1 CH3 stabilizes aglycosylated IgG4 CH2 without effector function

[0640] The proteins described in this section are derived from the 5c8 antibody and, unless otherwise indicated,

[0641] As described in detail in Example 5, IgG4-CH2 / IgG1-CH3 was expressed in CHO cells.

[0642] It was observed that the EAG2412 construct (N297Q IgG4-CH2 / IgG1-, i.e., 5c8 variable

[0643] Pharmacokinetic studies were performed in Sprague-Dawley rats to address the stability of

[0644] N297Q IgG4-CH2 / IgG1-CH3 has the same half-life as T299A IgG4 antibody

[0645] Table 12.1: IL culture proteins as measured by analytical size exclusion chromatography

[0646] Final amino acid substitution Yield (mg) monomer% pEAG2296 S228P / T299A / IgG1-CH3 7.24 98% pEAG2287 S228P / T299K / lgG1-CH3 14.2 100% EAG2412 S228P / N297Q / IgG1-CH3 13.75 99.30% YC407 S228P,T299A 4.07 96.90% CN579 S228P,T299K 11.55 90% EAG2391 N297Q 7.8 100%

[0647] Table 12.2: Melting temperatures of IgG4-CH2 / IgG1-CH3 constructs as measured

[0649] Table 12.3: Turbidity and % Monomer of Constructs at Various Time Points During Agitation

[0651] Table 12.4: FcyR affinity characterization of IgG4 / IgG1 variants (NB indicates no binding)

[0653] a No binding observed

[0654] Table 12.5: Pharmacokinetics of Stability Engineered Constructs in Rats

[0656] Example 10. T299 is a determinant of stability and effector function

[0657] The proteins described in this section are all derived from the 5c8 antibody and, unless otherwise indicated,

[0658] As described in detail in Example 5, IgG1 T299X and

[0659] A slight increase in N297X and T299K mutations (CN645, CN646, and CN647) was observed.

[0660] Table 13.1: IL culture proteins as measured by analytical size exclusion chromatography

[0661] Final amino acid substitution Yield (mg) monomer% CN647 N297D,T299K 7.4 100% CN646 N297S,T299K 30.47 98.50% CN645 N297P,T299K 9.3 100% EAG2389 T299Q 12.6 100% EAG2390 T299P 22.3 100% EAG2377 T299N 8.7 100% EAG2378 T299R 14.1 100.00% EAG2379 T299E 10.1 100% EAG2380 T299F 12.6 100%

[0662] Table 13.2: Melting Temperatures of T299X Constructs as Measured by DSC

[0664] Table 13.3: FcγR affinity characterization of T299X variants (NB indicates no binding)

[0667] Example 11. Stabilized Fc constructs show that the use of stability mutants is not related to Fab

[0668] The proteins described in this section contain the binding site derived from the 5c8 antibody.

[0669] The protein was produced and purified as described in Example 5. The protein was purified by DSC at pH 6.0.

[0670] The stabilized Fc aglycosylated construct was expressed in CHO cells as described in detail in Example 5.

[0671] Table 10.1: Protein content of 4 L culture as measured by analytical size exclusion chromatography

[0674] Table 10.2: Melting temperatures of Fc constructs as measured by DSC

[0676] Table 10.3: FcγR affinity characterization of T299X variants (NB indicates no binding)

[0678] Example 12

[0679] To produce a product with desirable properties, including thermal stability, less precipitation during purification, and

[0680] For example, the variable heavy chain of SEQ ID NO: 4 is coupled to a

[0681] Example 13. Stabilization as determined by hydrogen / deuterium exchange mass spectrometry and X-ray crystallography

[0682] Structure and dynamics contribute significantly to protein function. Understanding the underlying structural mechanisms is crucial for solving

[0683] A. Hydrogen / Deuterium Exchange Mass Spectrometry

[0684] Detection of hydrogen / deuterium exchange by mass spectrometry is a method for characterizing protein dynamics and conformation.

[0685] The antibody (at pH 6.0) was diluted with 50 mM sodium phosphate, 100 mM sodium chloride, D2O.

[0686] Intact IgG4.P vs. N297Q IgG4.P, N297Q

[0687] B. X-ray crystallography of stability-enhanced Fc constructs

[0688] EAG2476 construct (agly IgG4-Fc T299K, T307P, L309K, D399S)

[0689] The crystal structure of EAG2478 construct (agly IgG1 Fc T299K) was solved to

[0690] Example 14. Protein purification.

[0691] Stable expression of the gene with SEQ ID NO: 81 in Chinese hamster ovary (CHO) cells

[0692] Figure 22A Display light chain HP1 / 2 hG4P agly (N297Q, EU numbering) G1κ light chain

[0693] Figure 22B Display light chain HP1 / 2 hG4P agly (N297Q, EU numbering) G1 heavy chain

[0694] Figure 23A Includes amino acids from HP1 / 2 hG4P agly(N297Q)G1κ light chain (H1L3)

[0695] Figure 23B comprising a mature light chain having SEQ ID NO: 81 and a mature light chain having SEQ ID NO: 80

[0696] Use pyrogen-free containers and solutions throughout the purification process. Perform the purification process at room temperature.

[0697] Stable expression of HP1 / 2 hG4P agly in Chinese hamster ovary (CHO) cells

[0698] For purification, briefly, 7.5 L of HPLC containing approximately 10 g HP1 / 2 hG4P agly(N297Q)

[0699] The rProtein A elution pool was loaded onto a 150 mL TMAE column (EMD 1.16881.0500,

[0700] Example 15. Protein characterization.

[0701] The protein described in Example 14 was characterized by several different methods as discussed below.

[0702] A. Ultraviolet spectrum

[0703] Figure 24 A mature light chain (HP1 / 2 hG4P agly

[0704] B. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)

[0705] Figure 25 The mature light chain (HP1 / 2 hG4P agly

[0706] C. Isoelectric Focusing (IEF)

[0707] Figure 26 The mature light chain (HP1 / 2 hG4P agly

[0708] D. Analytical Size Exclusion Chromatography

[0709] Figure 27 The mature light chain (HP1 / 2 hG4P agly

[0710] E.Endotoxin

[0711] Charles River Endosafe PTS20 cartridges (0.05-5 EU / ml) were used according to the manufacturer

[0712] F. Differential Scanning Calorimetry (DSC)

[0713] Figures 28 to 30 The mature light chain (HP1 / 2 hG4P) having SEQ ID NO: 81 is shown.

[0714] Table 11. Figures 28 to 30 HP1 / 2 hG4P agly(N297Q)G1 measured in

[0716] Example 16. Other experimental analyses of proteins.

[0717] Study the product properties of two different HP1 / 2 proteins. The first construct, humanized

[0718] Table 12. Summary of the two engineered constructs

[0721] 900 mL of the constructs containing 72-122 mg / L as indicated in the table above (by Octet

[0722] Protein loss due to precipitation when neutralizing the four antibody preparations after the ProA step

[0723] Table 13. Percent precipitation of four engineered constructs

[0725] As shown in Table 13 above, the most notable difference was when the natalizumab G4P agly sample was

[0726] The four construct samples were characterized by SDS-PAGE and size exclusion chromatography (SEC).

[0727] Figure 32A The results of SEC analysis of the HP1 / 2 sample are shown. Figure 32B Show all four

[0728] Thus, consistent with the SDS-PAGE data, SEC analysis revealed that

[0729] The stability of the two HP1 / 2 samples was also characterized by differential scanning calorimetry (DSC).

[0730] The CH3 domain of HP1 / 2 G4P agly G1 is very stable, as shown by its Tm

[0731] In other words, HP1 / 2 G4P agly G1 (i.e., having the amino acid sequence of SEQ ID NO: 80)

[0732] Example 17: Clinical Pharmacokinetics of HP1 / 2 and First-in-Human Dose Prediction

[0733] Back-translational integration of clinical input can be used to enhance clinical pharmacokinetics and efficacy

[0734] HP1 / 2 (3 and 30 mg / kg) and NTZ (3 mg / kg) were administered to cynomolgus monkeys (n=18).

[0735] HP1 / 2 (4.73 μg / mL) formed the EC50 of drug binding to VLA (see Table 14) when compared with

[0736] Table 14. Model-Estimated PKPD Parameters for Tysabri and BIIB107 in Monkeys

[0738] Embedded Table a The inter-animal variability was expressed as the coefficient of variation. The standard error (SE) was expressed as the relative

[0739] b E0=100-E0; Emax=100-Emax.

[0740] These data indicate that HP1 / 2 binds to cynomolgus monkey α4 integrin with a higher affinity than human

[0741] like Figure 36 As shown in Figure 2, α4 integrin was found to be expressed on human and cynomolgus monkey lymphocytes.

[0742] Using a two-compartment model with linear and Michaelis-Menten elimination and direct E max

[0744] The PKPD parameter values ​​from the final “humanized” model were generated by a multivariate normal distribution.

[0745] Receptor occupancy of simulated HP1 / 2 and natalizumab after a single intravenous administration

[0746] In view of this Example 17, integration across two humanized anti-α4 integrin antibodies can be utilized

[0747] The embodiments of the present invention described above are intended to be exemplary only; numerous variations and Sequence Listing <110> Biogen MA Inc. <120> Anti-VLA-4 antibodies with reduced effector function <130> 2790-211 <160> 94 <170> PatentIn version 3.5 <210> 1 <211> 121 <212> PRT <213> Mediterranean house mouse (Mus spretus) <400> 1 Glu Val Gln Leu Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Lys Gln Arg Pro Glu Gln Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Lys Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn Thr Ala Trp 65 70 75 80 Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Thr Val Thr Val Ser Ser 115 120 <210> 2 <211> 98 <212> PRT <213> Homo sapiens <400> 2 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Val Ser Gly Tyr Thr Phe Thr Asp Tyr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Leu Val Asp Pro Glu Asp Gly Glu Thr Ile Tyr Ala Glu Lys Phe 50 55 60 Gln Gly Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95<00​​​​​​​​​ <220> <223> Synthetic polypeptide <400> 3 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Val Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Thr Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 4 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 4 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 5 <211> 121 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 5 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Ile 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Ala Thr Ile Thr Ala Asp Thr Ser Thr Asn Thr Ala Tyr 65 70 75 80 Leu Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser 115 120 <210> 6 <211> 107 <212> PRT <213> Mus spretus <400> 6 Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Thr Asn Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Thr Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 7 <211> 101 <212> PRT <213> Homo sapiens <400> 7 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ser Ser Gln Ser Val Leu Tyr Ser 20 25 30 Ser Asn Asn Lys Asn Tyr Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln 35 40 45 Pro Pro Lys Leu Leu Ile Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val 50 55 60 Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr 65 70 75 80 Ile Ser Ser Leu Gln Ala Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln 85 90 95 Tyr Tyr Ser Thr Pro 100 <210> 8 <211> 107<00020​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 9 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 9 Ser Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Thr Asn Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile[[ID=?]] 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 10 <211> 107 <??> PRT It seems there is a tag "??" in the original text which might be an error. I've translated it as "??" in the English version as well. You may want to double-check the original text for accuracy.<213> Artificial Sequence <220> <223> synthetic peptides <400> 10 Ser Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Thr Asn Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 11 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> synthetic peptides <400> 11 Ser Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Thr Asn Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <(210)> 12 <(211)> 107 <(212)> PRT <(213)> Homo sapiens <(400)> 12 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Gln Ala Ser Gln Asp Ile Lys Thr Tyr 20 25 30 Note: There seems to be a potential issue with the original text where the tags <210>, <211>, <212>, <213>, <400> might be in an incorrect format. They are typically written without the parentheses in patent text tagging. This translation is done as per the provided text with the current tag format.Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys Pro Pro Lys Leu Leu Ile 35 40 45 Ser Asp Ala Ser Gly Phe Gln Pro Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Ser Phe Thr Ile Thr Ser Leu Arg Pro 65 70 75 80 Asp Asp Thr Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Lys Val Pro Phe 85 90 95 Thr Phe Gly Pro Gly Lys Val Gly Phe Asn Arg 100 105 <210> 13 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 13 Asp Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Gln Ala Ser Gln Asp Ile Lys Thr Tyr 20 25 30 Leu Ser Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Asp Ala Ser Gly Phe Gln Pro Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Thr Tyr Tyr Cys Gln Gln Tyr Glu Lys Val Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys 100 105 <210> 14 <211> 228 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 14 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 15 <211> 235 <212> PRT <213> Homo sapiens <400> 15 Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp 1 5 10 15 Leu Ser Gly Ala Arg Cys Asp Ile Gln Met Thr Gln Ser Pro Ser Ser 20 25 30 Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Gln Ala Ser 35 40 45 Gln Asp Ile Lys Thr Tyr Leu Ser Trp Phe Gln Gln Lys Pro Gly Lys 50 55 60 Pro Pro Lys Leu Leu Ile Ser Asp Ala Ser Gly Phe Gln Pro Gly Val 65 70 75 80 Pro Ser Arg Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Ser Phe Thr 85 90 95 Ile Thr Ser Leu Arg Pro Asp Asp Thr Ala Thr Tyr Tyr Cys Gln Gln 100 105 110 Tyr Glu Lys Val Pro Phe Thr Phe Gly Pro Gly Lys Val Gly Phe Asn 115 120 125 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 130 135 140 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 145 150 155 160 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 165 170 175 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser 180 185 190 Thr Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu 195 200 205 Lys His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser 210 215 220 Pro Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 235 <210> 16 <211> 228 <212> PRT<9002221><213> Homo sapiens <400> 16 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 17 <211> 228 <212> PRT <213> Homo sapiens <400> 17 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Phe Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 18 <211> 227 <212> PRT <213> Homo sapiens <400> 18 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 19 <211> 306 <212> PRT <213> Homo sapiens <400> 19 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Phe 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 225 230 235 240 Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe 245 250 255 Ser Cys Ser Phe Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 260 265 270 Ser Leu Ser Leu Ser Leu Gly Gly Asn Val Phe Ser Cys Ser Phe Met 275 280 285 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 290 295 300 Leu Gly 305 <210> 20 <211> 227 <212> PRT <213> Homo sapiens <400> 20 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45<​​​​Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 21 <211> 227 <212> PRT <213> Homo sapiens <400> 21 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60<00^2416>Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125[[ID=*45]] Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Phe 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 22 <211> 227 <212> PRT <213> Homo sapiens <400> 22 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 It should be noted that there seems to be a small error in the number "195" in line , which is likely a typo and should probably be "195". This has been translated as "195" in the above translation while maintaining the integrity of the original text as much as possible.Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Phe 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 23 <211> 228 <212> PRT <213> Homo sapiens <400> 23 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Phe Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Glu Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Phe Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 24 <211> 228 <212> PRT <213> Homo sapiens <400> 24 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Phe Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu [[ID=​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 26 <211> 228 <212> PRT <213> Homo sapiens <400> 26 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 27 <211> 227 <212> PRT <213> Homo sapiens <400> 27 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Pro His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 28 <211> 227 <212> PRT <213> Homo sapiens <400> 28 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Met His Gln Asp Trp Leu<00> 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 29 <211> 227 <212> PRT <213> Homo sapiens <400> 29 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 30 <211> 227 <212> PRT <213> Homo sapiens <400> 30 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 31 <211> 227 <212> PRT <213> Homo sapiens <400> 31 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Met His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 32 <211> 227 <212> PRT <213> Homo sapiens <400> 32 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Pro Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 33 <211> 227 <212> PRT <213> Homo sapiens <400> 33 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 34 <211> 227 <212> PRT <213> Homo sapiens <400> 34 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Thr Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 35 <211> 227 <212> PRT <213> Homo sapiens <400> 35 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Pro Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 36 <211> 227 <212> PRT <213> Homo sapiens <400> 36 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 37 <211> 227 <212> PRT <213> Homo sapiens <400> 37 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 38 <211> 227 <212> PRT <213> Homo sapiens <400> 38 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Pro Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Leu Gly 225 <210> 39 <211> 228 <212> PRT <213> Homo sapiens <400> 39 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Pro Gly 225 <210> 40 <211> 228 <212> PRT <213> Homo sapiens <400> 40 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Pro Gly 225 <210> 41 <211> 228 <212> PRT <213> Homo sapiens <400> 41 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190<000313​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Pro Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Pro Gly 225 <210> 43 <211> 227 <212> PRT <213> Homo sapiens <400> 43 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45<00​​​​​​​​​​​​Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly 225 <210> 44 <211> 230 <212> PRT <213> Homo sapiens <400> 44 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp 50 55 60 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr 65 70 75 80 Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 85 90 95 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu 100 105 110 Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 115 120 125 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 130 135 140 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 145 150 155 160 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 165 170 175 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 180 185 190<{ Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 195 200 205 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 210 215 220 Leu Ser Leu Ser Pro Gly 225 230 <210> 45 <211> 231 <212> PRT <213> Homo sapiens <400> 45 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Thr Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 46 <211> 231 <212> PRT <213> Homo sapiens <400> 46 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val s 35 40 45 Val Asp Phe Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 47 <211> 231 <212> PRT <213> Homo sapiens <400> 47 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Leu Val 35 40 45 Thr Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 48 <211> 231 <212> PRT <213> Homo sapiens <400> 48 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Thr Asp Phe Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 49 <211> 229 <212> PRT <213> Homo sapiens <400> 49 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser Pro Asp Pro Val Lys Phe Asn Trp Tyr Val Asp Gly 50 55 60 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 65 70 75 80 Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 85 90 95 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 100 105 110 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 115 120 125 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 130 135 140 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 145 150 155 160 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 165 170 175 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 180 185 190 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 195 200 205 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 210 215 220<00{03416>Ser Leu Ser Pro Gly 225 <210> 50 <211> 229 <212> PRT <213> Homo sapiens <400> 50 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Leu Val 35 40 45 Thr Asp Val Ser Pro Asp Pro Val Lys Phe Asn Trp Tyr Val Asp Gly 50 55 60 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 65 70 75 80 Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 85 90 95 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 100 105 110 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 115 120 125 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 130 135 140 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 145 150 155 160 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 165 170 175 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 180 185 190 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 195 200 205 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 210 215 220 Ser Leu Ser Pro Gly 225 <210> 51 <211> 231 <212> PRT <213> Homo sapiens <400> 51 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Leu Val ​​​​​​​​​​​​​​​​​​​​​​Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 52 <211> 444 <212> PRT <213> Homo sapiens <400> 52 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 53 <211> 218 <212> PRT <213> Homo sapiens <400> 53 Asp Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Val Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Arg Val Ser Ser Ser 20 25 30 Thr Tyr Ser Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Ser Val Glu Pro Glu Asp Phe Ala Thr Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Ile Pro Pro Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 54 <211> 216 <212> PRT <213> Homo sapiens <400> 54 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val 210 215 <210> 55 <211> 228 <212> PRT <213> Homo sapiens <400> 55 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 56 <211> 228 <212> PRT <213> Homo sapiens <400> 56 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 57 <211> 228 <212> PRT <213> Homo sapiens <400> 57 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser 65 70 75 80 Ala Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 58 <211> 231 <212> PRT <213> Homo sapiens <400> 58 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Ala Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 59 <211> 227 <212> PRT <213> Homo sapiens <400> 59 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser 65 70 75 80 Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Pro 225 <210> 60 <211> 231 <212> PRT <213> Homo sapiens <400> 60 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 61 <211> 447 <212> PRT <213> Homo sapiens <400> 61 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Pro Ser Lys Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 62 <211> 447 <212> PRT <213> Homo sapiens <400> 62 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asp Ser Lys Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 63 <211> 447 <212> PRT <213> Homo sapiens <400> 63 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Ser Ser Lys Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 64 <211> 444 <212> PRT <213> Homo sapiens <400> 64 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 <210> 65 <211> 228 <212> PRT <213> Homo sapiens <400> 65 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe 1 5 10 15 Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr 20 25 30 Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val 35 40 45 Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val 50 55 60 Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser [[ID=2〗7]]65 70 75 80 Lys Tyr Arg Val Val Ser Val Leu Pro Val Lys His Gln Asp Trp Leu 85 90 95 Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser 100 105 110 Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro 115 120 125 Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln 130 135 140 Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala 145 150 155 160 Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr 165 170 175 Pro Pro Val Leu Ser Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu 180 185 190 Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser 195 200 205 Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser 210 215 220 Leu Ser Leu Gly 225 <210> 66 <211> 231 <212> PRT <213> Homo sapiens <400> 66 Glu Pro Lys Ser Ser Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 67 <211> 447 <212> PRT <213> Homo sapiens <400> 67 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Asn Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 68 <211> 447 <212> PRT <213> Homo sapiens <400> 68[[ID=1​​​​​​​​​​​​​​​​​​​​​​​​​​​​​​115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Arg Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 69 <211> 447 <212> PRT <213> Homo sapiens <400> 69 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Glu Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 70 <211> 447 <212> PRT <213> Homo sapiens <400> 70 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr [[ID=3B]]100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 [[ID=AB]]Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Phe Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 71 <211> 447 <212> PRT <213> Homo sapiens <400> 71 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Gln Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 72 <211> 447 <212> PRT <213> Homo sapiens <400> 72 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Pro Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 73 <211> 444 <212> PRT <213> Homo sapiens <400> 73 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Val Lys Pro Gly Ala 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Ile Phe Thr Ser Tyr 20 25 30 Tyr Met Tyr Trp Val Lys Gln Ala Pro Gly Gln Gly Leu Glu Trp Ile<{ 35 40 45 Gly Glu Ile Asn Pro Ser Asn Gly Asp Thr Asn Phe Asn Glu Lys Phe 50 55 60 Lys Ser Lys Ala Thr Leu Thr Val Asp Lys Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Ser Asp Gly Arg Asn Asp Met Asp Ser Trp Gly Gln Gly Thr 100 105 110 Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys 210 215 220 Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val Phe Leu 225 230 235 240 Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu 245 250 255 Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu Val Gln 260 265 270 Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys 275 280 285 Pro Arg Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val Ser Val Leu 290 295 300 Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys 305 310 315 320 Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys 325 330 335 Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser 340 345 350 Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys 355 360 365 Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln 370 375 380 Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly 385 390 395 400 Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg Trp Gln 405 410 415 Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn 420 425 430 His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 <210> 74 <211> 227 <212> PRT <213> Homo sapiens <400> 74 Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Pro Val 1 5 10 15 Ala Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu 20 25 30 Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser 35 40 45 Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu 50 55 60 Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser Thr 65 70 75 80 Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn 85 90 95 Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser 100 105 110 Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln 115 120 125 Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val 130 135 140 Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val 145 150 155 160 Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro 165 170 175 Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr 180 185 190 Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val 195 200 205 Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu 210 215 220 Ser Pro Gly 225 <210> 75 <211> 231 <212> PRT <213> Homo sapiens <400> 75 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asn Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 76 <211> 231 <212> PRT <213> Homo sapiens <400> 76 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Asp Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> seventy-seven <211> two hundred and thirty-one <212> PRT <213> Homo sapiens <400> seventy-seven Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Ser Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95 Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205 Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 78 <211> 231 <212> PRT <213> Homo sapiens <400> 78 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val 35 40 45 Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val 50 55 60 Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln 65 70 75 80 Tyr Pro Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln 85 90 95[[ID=A]] Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala 100 105 110 Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro 115 120 125 Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr 130 135 140 Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser 145 150 155 160 Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr 165 170 175 Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr 180 185 190 Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe 195 200 205<http: / / www.wipo.int / standards / XMLSchema / ST36 / schema / ST36-20080201.xsd>Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys 210 215 220 Ser Leu Ser Leu Ser Pro Gly 225 230 <210> 79 <211> 229 <212> PRT <213> Homo sapiens <400> 79 Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala 1 5 10 15 Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro 20 25 30 Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Leu Val 35 40 45 Thr Asp Phe Ser Pro Asp Pro Val Lys Phe Asn Trp Tyr Val Asp Gly 50 55 60 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn 65 70 75 80 Ser Lys Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 85 90 95 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro 100 105 110 Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 115 120 125 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 130 135 140 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 145 150 155 160 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 165 170 175 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 180 185 190 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 195 200 205 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 210 215 220 Ser Leu Ser Pro Gly 225 <210> 80 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 80 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 81 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 81 Ser Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val Thr Asn Asp 20 25 30 Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Ser Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Ala 65 70 75 80 Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Tyr 85 90 95 Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 82 <211> 107 <212> PRT <213> Homo sapiens <400> 82 Arg Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu 1 5 10 15 Gln Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe 20 25 30 Tyr Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln 35 40 45 Ser Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser ​​​​​​​​​​​​​​​​​​​​​​​​​​​​Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Gln Thr 65 70 75 80 Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Lys Val Glu Pro Lys Ser Cys Asp Lys Thr His Thr Cys Pro Pro Cys 100 105 110 Pro Ala Pro Glu Leu Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro 115 120 125 Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys 130 135 140 Val Val Val Asp Val Ser His Glu Asp Pro Glu Val Lys Phe Asn Trp 145 150 155 160 Tyr Val Asp Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu 165 170 175 Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu 180 185 190 His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn 195 200 205 Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly 210 215 220 Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu 225 230 235 240 Leu Thr Lys Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr 245 250 255 Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn 260 265 270 Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe 275 280 285 Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn 290 295 300 Val Phe Ser Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr 305 310 315 320 Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 325 330 <210> 84 <211> 327 <212> PRT <213> Homo sapiens <400> 84 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Ser Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Asn Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Gln Glu Glu Met Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Arg Leu Thr Val Asp Lys Ser Arg Trp Gln Glu Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Leu Gly Lys 325 <210> 85 <211> 326 <212> PRT <213> Artificial Sequence(Artificial Sequence) <220> <223> synthetic peptide <400> 85 Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg 1 5 10 15 Ser Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr 20 25 30 Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser 35 40 45 Gly Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser 50 55 60 Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr 65 70 75 80 Tyr Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys 85 90 95 Arg Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro 100 105 110 Glu Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys 115 120 125 Asp Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val 130 135 140 Asp Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp 145 150 155 160 Gly Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe 165 170 175 Gln Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp 180 185 190 Trp Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu 195 200 205 Pro Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg 210 215 220 Glu Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys 225 230 235 240 Asn Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp 245 250 255 Ile Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys 260 265 270 Thr Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser 275 280 285 Lys Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser 290 295 300 Cys Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser 305 310 315 320 Leu Ser Leu Ser Pro Gly 325 <210> 86 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 86 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Ser Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 87 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 87 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 88 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 88 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Note: There was a small error in the original text where "415" should be "415" and "0005166" should be "0005166". These have been corrected in the translation.Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Glu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 89 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 89 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly 210 215 220 Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro 260 265 270 Glu Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Ala Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 90 <211> 450 <212> PRT <213> Artificial Sequence <220> <223> Synthetic polypeptide <400> 90 Glu Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala 1 5 10 15 Thr Val Lys Ile Ser Cys Lys Ala Ser Gly Phe Asn Ile Lys Asp Thr 20 25 30 Tyr Met His Trp Val Gln Gln Ala Pro Gly Lys Gly Leu Glu Trp Met 35 40 45 Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr Lys Tyr Asp Pro Lys Phe 50 55 60 Gln Val Arg Val Thr Ile Thr Ala Asp Thr Ser Thr Asp Thr Ala Tyr 65 70 75 80 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Asp Gly Met Trp Val Ser Thr Gly Tyr Ala Leu Asp Phe Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Lys Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Leu Leu Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Gln Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly 450 <210> 91 <211> 702 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA sequence <400> 91 atggacttcg gcctgtccct ggtgttcctg gtgctgatcc tgaagggcgt gcagtgcagc 60 atcgtgatga cccagagccc cgacagcctg gccgtgagcc tgggcgagcg cgccaccatc 120 aactgcaagg ccagccagag cgtgaccaac gacgtggcct ggtatcagca gaagcccggc 180 cagcccccca agctgctgat ctactacgcc agcaaccgct acaccggcgt gcccgaccgc 240 ttcagcggca gcggctacgg caccgacttc accttcacca tcagcagcct ccaggccgag 300 gacgtggcca cctacttctg ccagcaagac tacagcagcc cctacacctt cggccagggc 360 accaaggtgg agatcaagcg tacggtggct gcaccatctg tcttcatctt cccgccatct 420 gatgagcagt tgaaatctgg aactgcctct gttgtgtgcc tgctgaataa cttctatccc 480 agagaggcca aagtacagtg gaaggtggat aacgccctcc aatcgggcaa ctcccaggag 540 agtgtcacag agcaggacag caaggacagc acctacagcc tcagctccac cctgacgctg 600 agcaaagcag actacgagaa acacaaagtc tacgcctgcg aagtcaccca tcagggcctg 660 tcctcgcccg tcacaaagag cttcaacagg ggagagtgtt aa 702 <210> 92 <211> 233 <212> PRT <213> Artificial Sequence <220> <223> Synthetic amino acid sequence[[ID=??]] <400> 92 Met Asp Phe Gly Leu Ser Leu Val Phe Leu Val Leu Ile Leu Lys Gly 1 5 10 15 Val Gln Cys Ser Ile Val Met Thr Gln Ser Pro Asp Ser Leu Ala Val 20 25 30 Note: There seems to be an issue with the tag "??" in the original text which is not a standard tag. It's left as is in the translation for the sake of maintaining the original structure. If this is an error in the original, it should be corrected before translation for a more accurate result. Ser Leu Gly Glu Arg Ala Thr Ile Asn Cys Lys Ala Ser Gln Ser Val 35 40 45 Thr Asn Asp Val Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys 50 55 60 Leu Leu Ile Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg 65 70 75 80 Phe Ser Gly Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser 85 90 95 Leu Gln Ala Glu Asp Val Ala Thr Tyr Phe Cys Gln Gln Asp Tyr Ser 100 105 110 Ser Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Glu Ile Lys Arg Thr 115 120 125 Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu 130 135 140 Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro 145 150 155 160 Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly 165 170 175 Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr 180 185 190 Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His 195 200 205 Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val 210 215 220 Thr Lys Ser Phe Asn Arg Gly Glu Cys 225 230 <210> 93 <211> 1410 <212> DNA <213> Artificial Sequence <220> <223> Synthetic DNA Sequence <400> 93 atggatatgc gcgtgcctgc ccaacttctc ggacttctcc tcctttggct gcctggagcc 60 cgatgtgagg tgcagctggt gcagagcggc gccgaggtga agaagcccgg cgccaccgtg 120 aagatcagct gcaaggccag cggcttcaac atcaaggaca cctacatgca ctgggtgcag 180 caggcccccg gcaagggcct ggagtggatg ggccgcatcg accccgccag cggcgacacc 240 aaatacgacc ccaagttcca agtccgggtg accatcaccg ccgacaccag caccgacacc 300 gcctacatgg agctgagcag cctgcgcagc gaggacaccg ccgtgtacta ctgcgccgac 360 ggcatgtggg tcagcaccgg ctacgccctg gacttctggg gccagggcac cctggtgacc 420 gtctcgagcg ctagtaccaa gggcccatcg gtcttccccc tggcgccctg ctcccggagc 480 acctccgaga gcacagccgc cctgggctgc ctggtcaagg actacttccc cgaacctgtg 540 acggtgtcgt ggaactcagg cgccctgacc agcggcgtgc acaccttccc ggctgtccta 600 caatcctcag gactctactc cctctcttcc gtggtgaccg tgccctccag cagcttgggc 660 acgaagacct acacctgtaa cgtagatcac aagcccagca acaccaaggt ggacaagaga 720 gttgagtcca aatatggtcc cccatgccca ccttgcccag cacctgagtt cctgggggga 780 ccatcagtct tcctgttccc cccaaaaccc aaggacactc tcatgatctc ccggacccct 840 gaggtcactt gcgtggtggt ggatgtgagc caggaagacc ccgaggtcca gtttaactgg 900 tacgtggatg gcgtggaagt ccacaatgcc aagacaaagc cgcgggagga gcagttccaa 960 agcacgtacc gtgtggtcag cgtcctcacc gtcctgcacc aagactggct gaacggcaag 1020 gagtacaagt gcaaggtgtc caacaaaggc ctcccgtcct ccatcgagaa aaccatctcc 1080 aaagccaaag ggcagccccg agaaccacag gtgtacaccc tgcccccatc gcgggatgag 1140 ctgaccaaga accaggtctc gctgacctgc ctggtcaaag gcttctatcc ctccgacatt 1200 gccgtggagt gggagagcaa tgggcagccg gagaacaact acaagaccac gcctcccgtg 1260 ttggactccg acggctcctt ctttctctac tccaaactca ccgtggacaa gagcaggtgg 1320 cagcagggga acgtcttctc atgctccgtg atgcatgagg ctctgcacaa ccactacacg 1380 caaaaaagcc tctccctcag cccgggctga 1410 <210> 94 <211> 469 <212> PRT <213> Artificial Sequence <220> <223> Synthetic amino acid sequence <400> 94 Met Asp Met Arg Val Pro Ala Gln Leu Leu Gly Leu Leu Leu Leu Trp 1 5 10 15 Leu Pro Gly Ala Arg Cys Glu Val Gln Leu Val Gln Ser Gly Ala Glu 20 25 30 Val Lys Lys Pro Gly Ala Thr Val Lys Ile Ser Cys Lys Ala Ser Gly 35 40 45 Phe Asn Ile Lys Asp Thr Tyr Met His Trp Val Gln Gln Ala Pro Gly 50 55 60 Lys Gly Leu Glu Trp Met Gly Arg Ile Asp Pro Ala Ser Gly Asp Thr 65 70 75 80 Lys Tyr Asp Pro Lys Phe Gln Val Arg Val Thr Ile Thr Ala Asp Thr 85 90 95 Ser Thr Asp Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp 100 105 110 Thr Ala Val Tyr Tyr Cys Ala Asp Gly Met Trp Val Ser Thr Gly Tyr 115 120 125 Ala Leu Asp Phe Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Ala 130 135 140 Ser Thr Lys Gly Pro Ser Val Phe Pro Leu Ala Pro Cys Ser Arg Ser 145 150 155 160 Thr Ser Glu Ser Thr Ala Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe 165 170 175 Pro Glu Pro Val Thr Val Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly 180 185 190 Val His Thr Phe Pro Ala Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu 195 200 205 Ser Ser Val Val Thr Val Pro Ser Ser Ser Leu Gly Thr Lys Thr Tyr 210 215 220 Thr Cys Asn Val Asp His Lys Pro Ser Asn Thr Lys Val Asp Lys Arg 225 230 235 240 Val Glu Ser Lys Tyr Gly Pro Pro Cys Pro Pro Cys Pro Ala Pro Glu 245 250 255 Phe Leu Gly Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp 260 265 270 Thr Leu Met Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp 275 280 285 Val Ser Gln Glu Asp Pro Glu Val Gln Phe Asn Trp Tyr Val Asp Gly 290 295 300 Val Glu Val His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Phe Gln 305 310 315 320 Ser Thr Tyr Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp 325 330 335 Leu Asn Gly Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Gly Leu Pro 340 345 350 Ser Ser Ile Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu 355 360 365 Pro Gln Val Tyr Thr Leu Pro Pro Ser Arg Asp Glu Leu Thr Lys Asn 370 375 380 Gln Val Ser Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile 385 390 395 400 Ala Val Glu Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr 405 410 415 Thr Pro Pro Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys 420 425 430 Leu Thr Val Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys 435 440 445 Ser Val Met His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu 450 455 460 Ser Leu Ser Pro Gly 465

Claims

1. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) the variable light chain of SEQ ID NO: 11; (b) the variable heavy chain of SEQ ID NO: 4; (c) the constant light chain of SEQ ID NO: 82; and (d) a chimeric Fc region, comprising a hinge, a CH1 domain and a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising a substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; a substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region.

2. A recombinant anti-α4 antibody or α4 binding fragment as described in claim 1, wherein the antibody or fragment has increased thermal stability compared to an antibody comprising: (a) a variable light chain of SEQ ID NO: 11; (b) a variable heavy chain of SEQ ID NO: 4; (c) a constant light chain of SEQ ID NO: 82; and (d) an Fc region comprising a hinge, a CH1 domain, a CH2 domain, and a CH3 domain of an IgG antibody of the IgG4 isotype, wherein the Fc region comprises a substitution of a non-asparagine residue at position 297 by EU numbering (position 314 by Kabat numbering).

3. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) the heavy chain of SEQ ID NO: 80; and (b) the light chain of SEQ ID NO:

81.

4. A polynucleotide encoding a protein comprising: (a) the variable light chain of SEQ ID NO: 11; (b) the variable heavy chain of SEQ ID NO: 4; (c) the constant light chain of SEQ ID NO: 82; and (d) a chimeric Fc region comprising a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising a substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; a substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region.

5. A polynucleotide encoding a protein comprising: (a) the heavy chain of SEQ ID NO: 80; and (b) the light chain of SEQ ID NO:

81.

6. Use of a recombinant anti-α4 antibody in the preparation of a medicament for alleviating symptoms in a patient suffering from multiple sclerosis, wherein the recombinant anti-α4 antibody comprises: (a) a variable light chain of SEQ ID NO: 11; (b) a variable heavy chain of SEQ ID NO: 4; (c) a constant light chain of SEQ ID NO: 82; and (d) a chimeric Fc region, wherein the chimeric Fc region comprises a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, wherein the chimeric Fc region comprises a substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; a substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region.

7. Use of a recombinant anti-α4 antibody in the preparation of a medicament for alleviating symptoms in a patient suffering from multiple sclerosis, The recombinant anti-α4 antibody comprises: (a) a heavy chain of SEQ ID NO: 80; and (b) a light chain of SEQ ID NO:

81.

8. The use according to claim 7, wherein the multiple sclerosis is a relapsing form of multiple sclerosis.

9. The use according to claim 8, wherein the relapsing form of multiple sclerosis is clinically isolated syndrome, relapsing remitting multiple sclerosis or active secondary progressive multiple sclerosis.

10. The use according to claim 7, wherein the multiple sclerosis is primary progressive multiple sclerosis or progressive relapsing multiple sclerosis.

11. The use according to claim 7, wherein the multiple sclerosis is an active form of multiple sclerosis, including an active relapsing form of multiple sclerosis.

12. The use according to claim 7, wherein the patient is a human.

13. A host cell transfected with the following polynucleotides: (a) a polynucleotide encoding an antibody heavy chain, the antibody heavy chain comprising the variable heavy chain of SEQ ID NO: 4; and a chimeric Fc region, the chimeric Fc region comprising a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising a substitution of glutamine (Q) at EU numbering position 297 (Kabat numbering position 314) in the CH2 region; a substitution of proline (P) at EU numbering amino acid position 228 (Kabat numbering position 241) in the hinge region; and a deletion of lysine (K) at EU numbering position 447 (Kabat numbering position 478) in the CH3 region; and (b) a polynucleotide encoding an antibody light chain, wherein the antibody light chain comprises a variable light chain of SEQ ID NO: 11 and a constant light chain of SEQ ID NO:

82.

14. A host cell transfected with: (a) a polynucleotide encoding the heavy chain of the antibody of SEQ ID NO: 80; and (b) a polynucleotide encoding the light chain of SEQ ID NO:

81.

15. The host cell of claim 13 or 14, wherein the host cell is a Chinese hamster ovary cell.

16. A method for making a recombinant anti-α4 antibody or an α4-binding fragment thereof, the method being achieved by: providing a host cell transfected with the following polynucleotides: (a) a polynucleotide encoding an antibody heavy chain, the antibody heavy chain comprising the variable heavy chain of SEQ ID NO: 4; and a chimeric Fc region, the chimeric Fc region comprising a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising a substitution of glutamine (Q) at EU numbering position 297 (Kabat numbering position 314) in the CH2 region; a substitution of proline (P) at EU numbering amino acid position 228 (Kabat numbering position 241) in the hinge region; and a deletion of lysine (K) at EU numbering position 447 (Kabat numbering position 478) in the CH3 region, the polynucleotide being positioned for expression in the cell; and (b) a polynucleotide encoding an antibody light chain comprising a variable light chain of SEQ ID NO: 11 and a constant light chain of SEQ ID NO: 82, wherein the polynucleotide is positioned for expression in the cell.

17. A method for producing a recombinant anti-α4 antibody or an α4-binding fragment thereof, the method being achieved by: A host cell is provided which is transfected with: (a) a polynucleotide encoding the heavy chain of the antibody of SEQ ID NO: 80, wherein the polynucleotide is positioned to be expressed in the cell; ; and (b) a polynucleotide encoding the light chain of SEQ ID NO: 81, said polynucleotide being positioned for expression in said cell; as well as The transfected host cells are cultured to produce the recombinant anti-α4 antibody molecule or α4-binding fragment thereof.

18. The method of claim 16 or 17, wherein the host cell is a Chinese hamster ovary cell.

19. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) the variable light chain of SEQ ID NO: 11; (b) the variable heavy chain of SEQ ID NO: 4; (c) the constant light chain of SEQ ID NO: 82; (d) a chimeric Fc region comprising a hinge, a CH1 domain, and a CH2 domain from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, the chimeric Fc region comprising: a substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; a substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region; and (e) the recombinant anti-α4 antibody or α4-binding fragment thereof has reduced susceptibility to perturbation relative to an antibody or binding fragment comprising a wild-type IgG4 constant region.

20. A recombinant anti-α4 antibody or α4 binding fragment as described in claim 19, wherein the antibody or fragment has increased thermal stability compared to an antibody comprising: (a) a variable light chain of SEQ ID NO: 11; (b) a variable heavy chain of SEQ ID NO: 4; (c) a constant light chain of SEQ ID NO: 82; and (d) an Fc region comprising a hinge, a CH1 domain, a CH2 domain, and a CH3 domain of an IgG antibody of the IgG4 isotype, wherein the Fc region comprises a substitution of a non-asparagine residue at position 297 by EU numbering (position 314 by Kabat numbering).

21. A recombinant anti-α4 antibody or an α4-binding fragment thereof, comprising: (a) the heavy chain of SEQ ID NO: 80; and (b) the light chain of SEQ ID NO: 81; The recombinant anti-α4 antibody or α4 binding fragment thereof has reduced susceptibility to perturbation relative to an antibody or binding fragment comprising a wild-type IgG4 constant region.

22. A method for producing a recombinant anti-α4 antibody or α4 binding fragment thereof having reduced susceptibility to perturbation relative to an antibody or binding fragment comprising a wild-type IgG4 constant region, the method include: A host cell is provided that is transfected with: (a) a polynucleotide encoding the heavy chain of the antibody of SEQ ID NO: 80, the polynucleotide being positioned for expression in the cell; and (b) a polynucleotide encoding the light chain of SEQ ID NO: 81, said polynucleotide being positioned for expression in said cell; as well as The transfected host cells are cultured to produce the recombinant anti-α4 antibody molecule or α4-binding fragment thereof.

23. The method of claim 22, wherein the host cell is a Chinese hamster ovary cell.

24. Use of a recombinant anti-α4 antibody in the preparation of a medicament for treating a patient suffering from epilepsy, wherein the recombinant anti-α4 antibody comprises: (a) a variable light chain of SEQ ID NO: 11; (b) a variable heavy chain of SEQ ID NO: 4; (c) a constant light chain of SEQ ID NO: 82; and (d) a chimeric Fc region, wherein the chimeric Fc region comprises a hinge, CH1 and CH2 domains from an IgG antibody of the IgG4 isotype and a CH3 domain from an IgG antibody of the IgG1 isotype, wherein the chimeric Fc region comprises a substitution of glutamine (Q) at position 297 by EU numbering (position 314 by Kabat numbering) in the CH2 region; a substitution of proline (P) at amino acid position 228 by EU numbering (position 241 by Kabat numbering) in the hinge region; and a deletion of lysine (K) at position 447 by EU numbering (position 478 by Kabat numbering) in the CH3 region.

25. Use of a recombinant anti-α4 antibody in the preparation of a medicament for treating a patient suffering from epilepsy, The recombinant anti-α4 antibody comprises: (a) a heavy chain of SEQ ID NO: 80; and (b) a light chain of SEQ ID NO:

81.

26. The use according to claim 25, wherein the epilepsy is drug-resistant epilepsy.

27. The use according to claim 25 or 26, wherein the patient is a human.